Expression of CD30 on CD117++ MCs in patients with mastocytosis
| No. . | Sex . | Age, y . | Diagnosis . | Serum tryptase, ng/mL . | CD30 surface expression on MCs (MFI ratio) . | CD30 IHC . |
|---|---|---|---|---|---|---|
| 1 | F | 68 | ISM | 42 | +(3.7) | ± |
| 2 | F | 63 | ISM | 32.7 | +(3.05) | ± |
| 3 | M | 50 | ISM | 19.7 | +(3.02) | ± |
| 4 | F | 63 | ISM | 77.8 | ±(1.94) | ± |
| 5 | M | 56 | ISM | 289 | ±(1.88) | + |
| 6 | F | 43 | ISM | 36.2 | ±(1.76) | ± |
| 7 | M | 55 | ISM | 124 | ±(2.03) | + |
| 8 | F | 53 | ISM | 61.2 | ±(2.44) | − |
| 9 | M | 24 | ISM | 53.7 | ±(2.08) | ± |
| 10 | M | 39 | ISM | 106 | ±(2.41) | ± |
| 11 | M | 47 | ISM | 82.5 | ±(2.00) | ± |
| 12 | M | 53 | ISM | 40.9 | ±(2.30) | ± |
| 13 | F | 35 | ISM | 34.1 | ±(1.57) | − |
| 14 | F | 57 | ISM | 11.2 | ±(1.58) | − |
| 15 | F | 57 | ISM | 55.1 | ±(2.23) | ± |
| 16 | M | 59 | ISM | 42.9 | ±(1.53) | − |
| 17 | M | 52 | ISM | 47.4 | ±(1.63) | ± |
| 18 | M | 64 | ISM | 33.5 | ±(2.08) | + |
| 19 | F | 36 | ISM | 19.5 | −(0.59) | − |
| 20 | F | 41 | ISM | 34.9 | −(1.12) | ± |
| 21 | F | 65 | ISM | 160 | −(1.33) | − |
| 22 | M | 45 | ISM | 31.1 | −(1.31) | ± |
| 23 | F | 47 | ISM | 28.8 | −(1.42) | ± |
| 24 | F | 38 | ISM | 16.8 | −(0.77) | ± |
| 25 | M | 29 | ISM | 31.1 | −(1.44) | − |
| 26 | M | 64 | ISM-AHNMD | 13.3 | ±(2.46) | − |
| 27 | M | 65 | ISM-AHNMD | 37.8 | −(0.98) | ± |
| 28 | F | 70 | ISM-AHNMD | 23 | −(0.83) | ± |
| 29 | M | 63 | ASM-AHNMD | 80 | +(8.93) | + |
| 30 | M | 70 | ASM-AHNMD | 48 | ±(1.64) | ± |
| 31 | F | 73 | ISM-AHNMD | 67.5 | +(5.8) | + |
| 32 | M | 75 | ASM | 789 | ++(12.93) | n.t. |
| 33 | M | 68 | ASM | 152 | +(3.94) | ± |
| 34 | F | 79 | ASM | 146 | +(3.50) | − |
| 35 | M | 66 | ASM | 103 | +(6.23) | ± |
| 36 | M | 71 | ASM | 113 | ±(1.98) | + |
| 37 | M | 74 | ASM | 152 | −(1.24) | − |
| 38 | F | 59 | ASM | 138 | −(1.43) | ± |
| 39 | F | 48 | MCL | 332 | +(9.79) | + |
| 40 | F | 62 | MCL | 547 | +(8.77) | ± |
| 41 | M | 75 | MCL | 431 | +(3.14) | + |
| 42 | M | 58 | MCL | 151 | +(3.04) | + |
| 43 | F | 54 | MCL | 904 | −(0.87) | − |
| 44 | F | 71 | MCL | 113 | −(1.4) | ± |
| 45 | M | 63 | MCL | 767 | −(1.05) | + |
| 46 | M | 44 | Normal BM | 35.5 | −(0.99) | − |
| 47 | M | 34 | Normal BM | 20.1 | −(1.31) | − |
| 48 | F | 32 | Normal BM | 14.8 | +(3.08)* | − |
| 49 | M | 53 | Normal BM | 18.1 | −(0.76) | − |
| 50 | F | 67 | Normal BM | 33.8 | −(1.1) | − |
| 51 | F | 51 | Normal BM | 21.1 | −(1.01) | − |
| No. . | Sex . | Age, y . | Diagnosis . | Serum tryptase, ng/mL . | CD30 surface expression on MCs (MFI ratio) . | CD30 IHC . |
|---|---|---|---|---|---|---|
| 1 | F | 68 | ISM | 42 | +(3.7) | ± |
| 2 | F | 63 | ISM | 32.7 | +(3.05) | ± |
| 3 | M | 50 | ISM | 19.7 | +(3.02) | ± |
| 4 | F | 63 | ISM | 77.8 | ±(1.94) | ± |
| 5 | M | 56 | ISM | 289 | ±(1.88) | + |
| 6 | F | 43 | ISM | 36.2 | ±(1.76) | ± |
| 7 | M | 55 | ISM | 124 | ±(2.03) | + |
| 8 | F | 53 | ISM | 61.2 | ±(2.44) | − |
| 9 | M | 24 | ISM | 53.7 | ±(2.08) | ± |
| 10 | M | 39 | ISM | 106 | ±(2.41) | ± |
| 11 | M | 47 | ISM | 82.5 | ±(2.00) | ± |
| 12 | M | 53 | ISM | 40.9 | ±(2.30) | ± |
| 13 | F | 35 | ISM | 34.1 | ±(1.57) | − |
| 14 | F | 57 | ISM | 11.2 | ±(1.58) | − |
| 15 | F | 57 | ISM | 55.1 | ±(2.23) | ± |
| 16 | M | 59 | ISM | 42.9 | ±(1.53) | − |
| 17 | M | 52 | ISM | 47.4 | ±(1.63) | ± |
| 18 | M | 64 | ISM | 33.5 | ±(2.08) | + |
| 19 | F | 36 | ISM | 19.5 | −(0.59) | − |
| 20 | F | 41 | ISM | 34.9 | −(1.12) | ± |
| 21 | F | 65 | ISM | 160 | −(1.33) | − |
| 22 | M | 45 | ISM | 31.1 | −(1.31) | ± |
| 23 | F | 47 | ISM | 28.8 | −(1.42) | ± |
| 24 | F | 38 | ISM | 16.8 | −(0.77) | ± |
| 25 | M | 29 | ISM | 31.1 | −(1.44) | − |
| 26 | M | 64 | ISM-AHNMD | 13.3 | ±(2.46) | − |
| 27 | M | 65 | ISM-AHNMD | 37.8 | −(0.98) | ± |
| 28 | F | 70 | ISM-AHNMD | 23 | −(0.83) | ± |
| 29 | M | 63 | ASM-AHNMD | 80 | +(8.93) | + |
| 30 | M | 70 | ASM-AHNMD | 48 | ±(1.64) | ± |
| 31 | F | 73 | ISM-AHNMD | 67.5 | +(5.8) | + |
| 32 | M | 75 | ASM | 789 | ++(12.93) | n.t. |
| 33 | M | 68 | ASM | 152 | +(3.94) | ± |
| 34 | F | 79 | ASM | 146 | +(3.50) | − |
| 35 | M | 66 | ASM | 103 | +(6.23) | ± |
| 36 | M | 71 | ASM | 113 | ±(1.98) | + |
| 37 | M | 74 | ASM | 152 | −(1.24) | − |
| 38 | F | 59 | ASM | 138 | −(1.43) | ± |
| 39 | F | 48 | MCL | 332 | +(9.79) | + |
| 40 | F | 62 | MCL | 547 | +(8.77) | ± |
| 41 | M | 75 | MCL | 431 | +(3.14) | + |
| 42 | M | 58 | MCL | 151 | +(3.04) | + |
| 43 | F | 54 | MCL | 904 | −(0.87) | − |
| 44 | F | 71 | MCL | 113 | −(1.4) | ± |
| 45 | M | 63 | MCL | 767 | −(1.05) | + |
| 46 | M | 44 | Normal BM | 35.5 | −(0.99) | − |
| 47 | M | 34 | Normal BM | 20.1 | −(1.31) | − |
| 48 | F | 32 | Normal BM | 14.8 | +(3.08)* | − |
| 49 | M | 53 | Normal BM | 18.1 | −(0.76) | − |
| 50 | F | 67 | Normal BM | 33.8 | −(1.1) | − |
| 51 | F | 51 | Normal BM | 21.1 | −(1.01) | − |
Score of antibody reactivity by flow cytometry: ++, MFI ratio 10-100; +, MFI ratio 3.01-9.99; ±, MFI ratio 1.51-3; −, MFI ratio <1.5.
Score of antibody reactivity by IHC: +, most cells (>50%) strongly reactive; ±, most cells (>50%) weakly reactive; −, <10% of cells reactive.
F, female; M, male; n.t., not tested.
In this patient, serum tryptase was slightly elevated and very few atypical MCs were found, but no KIT mutation was detected and no histologic evidence of SM could be substantiated.